SESSION TITLE: Pulmonary Vascular Disease
SESSION TYPE: Case Report Poster
PRESENTED ON: Sunday, April 17, 2016 at 11:45 AM - 12:45 PM
INTRODUCTION: Prostacyclin therapy remains the drug of choice for progressive pulmonary arterial hypertension (PAH) with New York Heart Association class IV patients. Persons presenting with worsening kidney function are often viewed as experiencing disease progression. This is an unusual case of a patient who developed worsening renal failure with up-titration of intravenous (IV) epoprostenol despite significant improvement of the hemodynamic markers and his functional class.